Trump cuts drug price deal with Regeneron
Summary
President Trump announced a deal with drug company Regeneron to lower prices on certain medicines. This deal is the last in a series of agreements with 17 companies aimed at reducing drug costs for Medicaid patients and some others.Key Facts
- President Trump secured a drug price deal with Regeneron, completing agreements with 17 drug manufacturers.
- These deals aim to lower prices for certain drugs offered to Medicaid and cash-paying patients using the TrumpRx website.
- The administration says the combined agreements cover 86% of brand-name drugs.
- Most discounts do not apply to people with private insurance or Medicare.
- Experts say Medicaid prices are already low, so the discounts may not significantly affect drug companies’ profits.
- Democrats want the details of these confidential agreements made public to check their impact.
- Smaller biotech companies might also make deals to avoid new tariffs on drugs.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.